Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

January 8, 2020January 8, 2020

Review Recommends International Consensus be Reached on What Constitutes PH in Newborns

News, PH News

An international consensus is lacking about what constitutes pulmonary hypertension (PH) in newborns, according to a review study, which recommends the use of standardized criteria to define the disease ... Read more

December 16, 2019December 16, 2019

Antiarrhythmic Tikosyn May be Repurposed to Treat PAH, Study Suggests

News

Tikosyn (dofetilide), a medicine approved by the U.S. Food and Drug Administration (FDA) to treat heart arrhythmias, may be used to treat pulmonary arterial hypertension (PAH), a recent study ... Read more

December 13, 2019December 13, 2019

Bioelectronic Medicine May Open New Therapeutic Avenues for PAH, Review Says

News, PAH News

Bioelectronic medicine is a promising new therapeutic approach to treat pulmonary arterial hypertension (PAH), according to a recent review study. The review, “Pulmonary arterial hypertension: the case for a ... Read more

November 20, 2019November 20, 2019

Antibody Able to Block Protein That Promotes PAH and May Bolster Existing Therapies, Study Finds

News, PAH News

An antibody that recognizes and blocks the activity of osteoprotegerin, a protein involved in the development of pulmonary arterial hypertension (PAH), was able to stop and even reverse disease ... Read more

October 21, 2019October 21, 2019

Higher Levels of sST2 Protein Linked to Poorer Outcomes in PH, Study Finds

News, PH News

Higher levels of a protein involved in certain immune responses, called soluble suppression of tumorigenicity-2 (sST2), are associated with more severe pulmonary hypertension (PH) and heart dysfunction, a study found. This ... Read more

September 18, 2019September 18, 2019

FDA Grants ‘Humanitarian Use Device’ Status to Tool for PAH Biopsies, Supporting Possible Approval

News

The Endoarterial Biopsy Catheter (EABC), a tool for performing biopsies on lung artery walls to better evaluate pulmonary arterial hypertension (PAH) in people and responses to treatment, has been ... Read more

September 11, 2019September 11, 2019

FDA Grants Breakthrough Device Status to SoniVie’s TIVUS System for PAH

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to SoniVie’s Therapeutic Intra-Vascular Ultrasound (TIVUS) System for the treatment of people with pulmonary arterial ... Read more

September 6, 2019September 6, 2019

Swedish Men and Women with IPAH Have Similar Survival Rates, Study Says

News, PAH News

Swedish men and women who have been diagnosed with idiopathic pulmonary arterial hypertension (IPAH) in recent years have similar survival rates, study says. The study, “Sex-specific differences and survival in ... Read more

August 30, 2019September 3, 2019

Common Lung Infections May Trigger PAH in People with At-risk Mutations, Rat Study Finds

News, PAH News

Lung inflammation caused by a seemingly treatable and common infection may drive the onset of pulmonary arterial hypertension (PAH) in people who carry genetic risk factors for the disease. ... Read more

August 29, 2019August 29, 2019

PDE5i-ERA Combo Improves Exercise Capacity, Reduces Risk of Death in PAH, Review Says

News, PAH News

A combination therapy of endothelin receptor antagonists (ERA) plus phosphodiesterase-5 inhibitors (PDE5i) — two different agents that induce blood vessels’ widening and relaxation —improves exercise capacity, and reduces the ... Read more

Pin It on Pinterest